Products

RhinoMAP
Precison Respiratory Diagnostics

In development - combining nasal microsampling, proteomics and AI to decode airway biology and predict treatment response.

Partner with us
our solution

Decoding airway biology to guide treatment

Nasal fluid proteomic profiling with AI-driven clinical interpretation. RhinoMAP is not simply a diagnostic tool but a multi-use platform addressing questions clinicians cannot resolve with observation alone.

It is a culmination of objective, reproducible assessments of airway biology to support real clinical decisions.

The platform is designed to:

Patient-treatment matching. Objective airway biomarker profiles help identify which patients are more likely to respond to a given treatment pathway, supporting decisions that would otherwise rely on clinical judgement alone.

Disease progression. Longitudinal biomarker trends can flag early signs of worsening airway disease, before symptoms alone would prompt a change in care.

Treatment response. Repeat sampling tracks whether a prescribed treatment is having the intended biological effect, giving clinicians objective feedback beyond symptom reporting.

Disease evolution where conditions overlap. Airway diseases like asthma and COPD can co-exist or transition over time; RhinoMAP's biomarker profile can highlight when a patient's condition may be shifting between or across these overlapping diagnoses.

what rhinomap aims to do

Three goals, one biology-driven platform

Monitor treatment response

Aims to give specialists objective, reproducible evidence of airway biological change, independent of clinician and patient-reported perception.

Predict response & side effects

Aims to personalise treatment plans using a patient's unique biology, reducing the current trial-and-error approach.

Triage overlapping conditions

Aims to resolve diagnostic uncertainty where conditions overlap, giving clinicians an objective biological basis for triage decisions that current tools alone cannot provide.

The platform

Four parts working as one

RhinoMAP · Integrated pipeline

Protected by 4 patent families with 8 active filings

ABEL Microsampler®

Nasal microsampling and sample collection.

PROTELLA

Multiplexed proteomics kits (Luminex / Olink).

MAP algorithms

AI-powered, multivariate biomarker analysis.

AIRLIE

Cloud platform for remote monitoring & secure data sharing.

availablitly

From research to pilot and launch

Phase 01 · Research

Pilot access

Early access for research partners.

2025/26

Phase 02 · Clinical

Pilot access

Clinical pilot deployment.

2027

Phase 03

Full launch

General availability.

2028
who is it for

Built with specialists and researchers

Target Audience

  • Respiratory specialists, otolaryngologists and allergists
  • Biotech companies and research groups
  • Pharma partners developing respiratory therapies
Focus Conditions

Common questions

Common questions

What is RhinoMAP?
An in-development precision diagnostics platform combining nasal microsampling, proteomics and machine learning to decode airway biology.

What does RhinoMAP aim to do?
It aims to monitor treatment response, predict response and side effects, and triage conditions with overlapping symptoms.

What is the platform made of?
ABEL nasal sampling, PROTELLA proteomics kits, AI-powered MAP algorithms, and the AIRLIE monitoring platform.

Is RhinoMAP available now?
It is in development — research pilot 2025/26, clinical pilot 2027, full launch 2028.

Is RhinoMAP approved or validated?
It is investigational technology and has not been approved by the FDA or any regulatory authority for diagnostic or clinical use.

Who is RhinoMAP for?
Respiratory specialists, otolaryngologists, allergists, biotech companies and researchers.

RhinoMAP is an investigational technology. It has not been approved by the FDA or any other regulatory authority for diagnostic or clinical use.